Abstract
BACE1, the aspartate protease that generates amyloid-β peptide (Aβ) in the brain of AD (Alzheimer’s disease) patients, has emerged as a pharmaceutically relevant target. Here, a fragment-based in silico approach has been adopted to design novel compounds with increased ligand efficiency for BACE1, before screening for brain permeability and toxicity. Fragments docked to the active site of BACE1 and sorted into two groups using binding energy cut-off, were joined to create novel ligands with binding energy lying in the range between -11.36 kcal/mol and -8.56 kcal/mol. Interestingly, QIN, a known inhibitor of BACE1 with an IC50 of 11nM, when docked to BACE1, shows a binding energy (-9.43 kcal/mol) lying within the range of the novel ligand-BACE1 complexes. The present strategy thus enabled the design of four novel inhibitors of BACE1 with favourable binding energy, brain permeability and no toxicity that might show promise as leads in future.
Keywords: BACE1, inhibitors, fragment, binding energy, design.
Graphical Abstract
Central Nervous System Agents in Medicinal Chemistry
Title:Fragment-based Designing for the Generation of Novel Leads Against BACE1
Volume: 15 Issue: 1
Author(s): Sucharita Das, Sandipan Chakraborty and Soumalee Basu
Affiliation:
Keywords: BACE1, inhibitors, fragment, binding energy, design.
Abstract: BACE1, the aspartate protease that generates amyloid-β peptide (Aβ) in the brain of AD (Alzheimer’s disease) patients, has emerged as a pharmaceutically relevant target. Here, a fragment-based in silico approach has been adopted to design novel compounds with increased ligand efficiency for BACE1, before screening for brain permeability and toxicity. Fragments docked to the active site of BACE1 and sorted into two groups using binding energy cut-off, were joined to create novel ligands with binding energy lying in the range between -11.36 kcal/mol and -8.56 kcal/mol. Interestingly, QIN, a known inhibitor of BACE1 with an IC50 of 11nM, when docked to BACE1, shows a binding energy (-9.43 kcal/mol) lying within the range of the novel ligand-BACE1 complexes. The present strategy thus enabled the design of four novel inhibitors of BACE1 with favourable binding energy, brain permeability and no toxicity that might show promise as leads in future.
Export Options
About this article
Cite this article as:
Das Sucharita, Chakraborty Sandipan and Basu Soumalee, Fragment-based Designing for the Generation of Novel Leads Against BACE1, Central Nervous System Agents in Medicinal Chemistry 2015; 15 (1) . https://dx.doi.org/10.2174/1871524915666150127122546
DOI https://dx.doi.org/10.2174/1871524915666150127122546 |
Print ISSN 1871-5249 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6166 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Editorial (Thematic Issue: Playing Well with Others! Initiating and Sustaining Successful Collaborations between Industry, Academia and Government)
Current Topics in Medicinal Chemistry Quality Indicators for Depression Treatment in Primary Care: A Systematic Literature Review
Current Psychiatry Reviews Dietary Assumption of Plant Polyphenols and Prevention of Allergy
Current Pharmaceutical Design Detection of Dendritic Spines Using Wavelet Packet Entropy and Fuzzy Support Vector Machine
CNS & Neurological Disorders - Drug Targets Substrate Specificity, Regulation, and Polymorphism of Human Cytochrome P450 2B6
Current Drug Metabolism The Updated Role of the Blood Brain Barrier in Subarachnoid Hemorrhage: From Basic and Clinical Studies
Current Neuropharmacology Errors in ADAS-Cog Administration and Scoring May Undermine Clinical Trials Results
Current Alzheimer Research G Protein β γ Subunits as Targets for Small Molecule Therapeutic Development
Combinatorial Chemistry & High Throughput Screening Should Overeating and Obesity be Classified as an Addictive Disorder in DSM-5?
Current Pharmaceutical Design Heterocyclic Secretase Inhibitors for the Treatment of Alzheimer’s Disease: An Overview
Central Nervous System Agents in Medicinal Chemistry The Use of Conformational Restriction in Medicinal Chemistry
Current Topics in Medicinal Chemistry Meet Our Editorial Board Member
CNS & Neurological Disorders - Drug Targets VEGF Mediates ApoE4-Induced Neovascularization and Synaptic Pathology in the Choroid and Retina
Current Alzheimer Research Graphical Abstracts:
Current Neuropharmacology The Contribution of Cerebral Vascular Neuropathology to Mild Stage of Alzheimer’s Dementia Using the NACC Database
Current Alzheimer Research Neuroprotective Gene Therapy for the Treatment of Inherited Retinal Degeneration
Current Gene Therapy Management of Obesity
Current Respiratory Medicine Reviews Alzheimer’s Disease and Molecular Chaperones: Current Knowledge and the Future of Chaperonotherapy
Current Pharmaceutical Design Adhesion Molecules as Potential Novel Biomarkers for Opioid Dependence
Current Pharmaceutical Design APP/PS1 Gene-Environment Noise Interaction Aggravates AD-like Neuropathology in Hippocampus <i>Via</i> Activation of the VDAC1 Positive Feedback Loop
Current Alzheimer Research